Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esreboxetine for Cognitive Function in Fibromyalgia
NCT00752505Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of esreboxetine in fibromyalgia (FM) (2 arms), sponsored by Pfizer. Primary endpoint: Computer based psychometric tests at 11 weeks. Started Aug 2008; status: completed.
02
Drugs
esreboxetine
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT00752505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00752505.